Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK)

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 24, 2014, Pages 5818-5823

  Trani, Giancarlo ^a   Barker, John J ^a   Bromidge, Steven M ^a   Brookfield, Frederick A ^a   Burch, Jason D ^b   Chen, Yuan ^b   Eigenbrot, Charles ^b   Heifetz, Alexander ^a   Ismaili, M Hicham A ^b   Johnson, Adam ^b   Krülle, Thomas M ^a   Mackinnon, Colin H ^a   Maghames, Rosemary ^a   McEwan, Paul A ^a   Montalbetti, Christian A G N ^a   Ortwine, Daniel F ^b   Pérez Fuertes, Yolanda ^a   Vaidya, Darshan G ^a   Wang, Xiaolu ^c   Zarrin, Ali A ^b   Pei, Zhonghua ^b   more..

^a EVOTEC UK LTD   (United Kingdom)

^b GENENTECH INC   (United States)

^c EVOTEC AG   (Germany)

Author keywords

ITK inhibitor; Sulfonylpyridine; T cell receptor

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDINE DERIVATIVE; SULFONYLPYRIDINE INHIBITOR; UNCLASSIFIED DRUG; EMT PROTEIN-TYROSINE KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE; PYRAZOLE DERIVATIVE; PYRIDINE; SULFONE;

ARTICLE; COMPUTER MODEL; CONFORMATION; CRYSTAL STRUCTURE; CYCLIZATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME CONFORMATION; HINGE REGION; HYDROGEN BOND; HYDROGENATION; JURKAT CELL LINE; MOLECULAR MODEL; NUCLEOPHILICITY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; KINETICS; METABOLISM; MOLECULAR DYNAMICS; PROTEIN TERTIARY STRUCTURE; SYNTHESIS;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; KINETICS; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 84912051971     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.10.020     Document Type: Article

References (12)

1. E.M. Schaeffer, J. Debnath, G. Yap, D. McVicar, X.C. Liao, D.R. Littman, A. Sher, H.E. Varmus, M.J. Lenardo, and P.L. Schwartzberg Science 284 1999 638
2. D.J. Fowell, K. Shinkai, X.C. Liao, A.M. Beebe, R.L. Coffman, D.R. Littman, and R.M. Locksley Immunity 11 1999 399
3. A.T. Miller, H.M. Wilcox, Z. Lai, and L.J. Berg Immunity 21 2004 67
4. C. Mueller, and A. August J. Immunol. 170 2003 5056
5. T.A. Lin, K.W. McIntyre, J. Das, C. Liu, K.D. O'Day, B. Penhallow, C.Y. Hung, G.S. Whitney, D.J. Shuster, X. Yang, R. Townsend, J. Postelnek, S.H. Spergel, J. Lin, R.V. Moquin, J.A. Furch, A.V. Kamath, H. Zhang, P.H. Marathe, J.J. Perez-Villar, A. Doweyko, L. Killar, J.H. Dodd, J.C. Barrish, J. Wityak, and S.B. Kanner Biochemistry 43 2004 11056
6. Alder, C. M.; Baldwin, I. R.; Barton, N. P.; Campbell, A. J.; Champigny, A. C.; Harling, J. D.; Maxwell, A. C.; Simpson, J. K.; Smith, I. E. D.; Tame, C. J.; Wilson, C.; Woolven, J. M. WO2010/106016 A1; C.M. Alder, M. Ambler, A.J. Campbell, A.C. Champigny, A.M. Deakin, J.D. Harling, C.A. Harris, T. Longstaff, S. Lynn, A.C. Maxwell, C.J. Mooney, C. Scullion, O.M.P. Singh, I.E.D. Smith, D.O. Somers, C.J. Tame, G. Wayne, C. Wilson, and J.M. Woolven ACS Med. Chem. Lett. 4 2013 948
7. GST-ITK and LCK-HIS full length enzymes were from Invitrogen (PV3875 and P3043, respectively) and substrate was BLK peptide (Ac-EFPIYDFLPAKKK-NH2). Reactions were carried out in a final volume of 51 μl with 50 mM HEPES buffer (pH 7.2), 15 mM MgCl2, 2 mM DTT, 0.015% Brij-35, 1 nM ITK or 0.5 nM LCK, 2 μM substrate, 20 μM ATP, and test article in a final concentration of 2% DMSO. After 35 min incubation at RT, reactions were stopped upon addition of 10 μl of 30% TCA. Samples were centrifuged (4350 rpm, 4 °C, 5 min) and subjected to LC/MS analysis on a Waters Acquity UPLC/TQD system equipped with a Waters Acquity UPLC BEH C18 (2.1 × 50 mm) 1.7 μm column (injection volume: 5 μl, column temperature: 60 °C, flow rate: 1 ml/min, solvent A: 0.1% formic acid in LC/MS grade water, solvent B: 0.1% formic acid in LC/MS grade ACN). Analytes were separated by applying a gradient from 15% to 32% solvent B within 0.7 min and detected in positive mode ESI-MS/MS by MRM (multiple reaction monitoring) of transitions 819.8/84.8 (BLK substrate) and 859.0/84.8 as well as 859.0/120.7 (phosphorylated BLK product). Ki values were determined using the Morrison tight-binding equation (J.W. William, and J.F. Morrison Methods Enzymol. 63 1979 437), modified to account for an ATP-competitive mechanism of inhibition and for the concentration of active kinase used
8. R.M. Pastor, J.D. Burch, S. Magnuson, D.F. Ortwine, Y. Chen, K. De La Torre, X. Ding, C. Eigenbrot, A. Johnson, M. Liimatta, Y. Liu, S. Shia, X. Wang, L.C. Wu, and Z. Pei Bioorg. Med. Chem. Lett. 24 2014 2448
9. J.D. Burch, K. Lau, J.J. Barker, F. Brookfield, Y. Chen, Y. Chen, C. Eigenbrot, C. Ellebrandt, M.H.A. Ismaili, A. Johnson, D. Kordt, C.H. MacKinnon, P.A. McEwan, D.F. Ortwine, D.B. Stein, X. Wang, D. Winkler, P.-W. Yuen, Y. Zhang, A.A. Zarrin, and Z. Pei J. Med. Chem. 57 2014 5714
10. C.H. MacKinnon, K. Lau, J.D. Burch, Y. Chen, J. Dines, X. Ding, C. Eigenbrot, A. Heifetz, A. Jaochico, A. Johnson, J. Kraemer, S. Kruger, T.M. Krülle, M. Liimatta, J. Ly, R. Maghames, C.A.G.N. Montalbetti, D.F. Ortwine, Y. Pérez-Fuertes, S. Shia, D.B. Stein, G. Trani, D.G. Vaidya, X. Wang, S.M. Bromidge, L.C. Wu, and Z. Pei Bioorg. Med. Chem. Lett. 23 2013 6331
11. A.P. Hill, and R.J. Young Drug Discovery Today 15 2010 648
12. Haydar, S. N.; Bothmann, H.; Ghiron, C.; Maccari, L.; Micco, I.; Nencini, A.; Zanaletti, R. WO 2010/009290 A1; Chem. Abstr. 2010, 152, 192109.